Ocular Therapeutix's current wet AMD treatment is dominated by anti-VEGF drugs, with EYLEA holding a 63% global market share in 2024. Read why OCUL stock is a sell.
The FDA approved Scancell's phase 3 trial of iSCIB1+ for advanced melanoma, focusing on progression-free survival as a ...
Good morning, everyone, and thank you for joining us today. Earlier this morning, we issued a press release outlining the positive topline results from our SOL-1 Phase III clinical trial of AXPAXLI, ...
Deupirfenidone, a potential new treatment for idiopathic pulmonary fibrosis, is set to be tested in a phase 3 trial this year after a successful phase 2b trial and meeting with the FDA, according to a ...
Biomed Industries, Inc. Announces Two NA-931 Phase 3 Trials, Targeting Durable Weight Loss & Lean-Mass Preservation ...
– Phase III trial informed by comprehensive KARDIA data set generated through three Phase II studies: KARDIA-1, KARDIA-2 and KARDIA-3 – – In the Phase II KARDIA-3 study, presented today as a late ...
X4 Pharmaceuticals has progressed significantly in its ongoing Phase 3 clinical trial, known as the 4WARD trial, targeting chronic neutropenia, aiming for full enrollment by the end of 2025 and ...
The FDA approved a phase 3 trial for iSCIB1+ in advanced melanoma, focusing on progression-free survival as a surrogate endpoint. Phase 2 SCOPE trial showed a 24% improvement in progression-free ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results